Genome Compiler

Company Overview

Snapshot

Founded in October 2011 by Omri Amirav-Drory, Roy Nevo, Nir Ben-Moshe, and Yogev Debbi, Genome Compiler operated with 1–10 employees. The company raised $5.75 million across one funding round from two investors before being acquired by Twist Bioscience in April 2016.

Business overview

Genome Compiler provided a SaaS-based, computer-aided design and collaboration platform specifically for synthetic biology. The company enabled users to design and order DNA programs directly, which could then be shipped as physical DNA for transforming living organisms with new functions. It offered access to various DNA synthesis providers, lab facility services, and a suite of bioinformatics tools and genetic repositories, serving markets within the Health Tech & Life Sciences sector, particularly in biotechnology and genomics.

Strategic signal

In April 2016, Genome Compiler was acquired by Twist Bioscience. This acquisition signaled a strategic consolidation within the synthetic biology and genomics sector, indicating the value placed on Genome Compiler's design and collaboration platform for advancing genetic engineering capabilities.

Company Intelligence Q&A

What is Genome Compiler's primary focus?

Genome Compiler focuses on providing a SaaS-based, computer-aided design and collaboration platform for synthetic biology, enabling users to design and order DNA programs.

When was Genome Compiler founded?

Genome Compiler was founded in October 2011.

Who were the founders of Genome Compiler?

Genome Compiler was co-founded by Omri Amirav-Drory, Roy Nevo, Nir Ben-Moshe, and Yogev Debbi.

What was a significant corporate milestone for Genome Compiler?

In April 2016, Genome Compiler was acquired by Twist Bioscience, a multinational company, in a strategic consolidation within the synthetic biology and genomics sector.

Which investors participated in Genome Compiler's funding round?

In June 2015, Genome Compiler received funding from Autodesk Investments and LionBird.